Table 2.
Early versus delayed ASCT.
| Author | Patient population (early ASCT versus delayed ASCT) | Induction regimen (early ASCT versus delayed ASCT) | Response (early versus delayed ASCT) | Progression-free survival (early versus delayed ASCT) | Overall survival (early versus delayed ASCT) |
|---|---|---|---|---|---|
| Fermand et al.16 | 185 patients (91 versus 94) | VAMP × 3–4# and ASCT versus VMCP till plateau and ASCT at relapse | 85.7% versus 55.5% | Median: 39 m versus 13 m | Median: 64.6 m versus 64 m (p = 0.92) |
| Kumar et al.17 | 285 patients (173 versus 112) | TD (n = 123) or RD (n = 167) × 4–6# followed by early or delayed ASCT | Median: 20 m versus 16 m (p = NS) | 4 years: 73% versus 73% (p = 0.3) | |
| Dunavin et al.18 | 167 patients (102 versus 65) | T-, R- or V-based induction followed by early or delayed ASCT | ⩾VGPR: 77% versus 55% (p = 0.003) | Median: 28 m versus 18 m (p = 0.11) | Median: NR versus 83 m (p = 0.45) |
| Remenyi et al.19 | 548 patients (377 versus 171) | 57% in early ASCT and 53.2% in delayed ASCT group received novel therapies | CR: 58.1% versus 46.8% (p = 0.016) | Median: 30.2 m versus 23.3 m (p = 0.036) | Median: 97.2 m versus 99.1 m (p = 0.77) |
| Attal et al.14 | 700 patients (350 versus 350) | VRD × 3# and ASCT + VRD × 2# versus VRD × 8# and ASCT at relapse | CR: 59% versus 48% (p = 0.03) | Median: 50 m versus 36 m (p < 0.001) | 4 years: 81% versus 82% |
ASCT, autologous stem-cell transplant; CR, complete response; NR, not reached; NS, non-significant; R, revilimid; RD, revilimid, dexamethasone; T, thalidomide; TD, thalidomide, dexamethasone; V, Velcade; VAMP, vincristine, adriamycin, melphalan, prednisolone; VGPR, very good partial response; VMCP, vincristine, melphalan, cyclophosphamide, prednisolone; VRD, Velcade, revilimid, dexamethasone.